Get the Stockscreener App
69.83
0.37%
-0.26
After Hours:
69.83
Disc Medicine Inc stock is traded at $69.83, with a volume of 339.43K.
It is down -0.37% in the last 24 hours and up +4.44% over the past month.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
See More
Previous Close:
$70.09
Open:
$70.13
24h Volume:
339.43K
Relative Volume:
0.73
Market Cap:
$2.67B
Revenue:
-
Net Income/Loss:
$-241.60M
P/E Ratio:
-10.55
EPS:
-6.6167
Net Cash Flow:
$-201.34M
1W Performance:
+2.18%
1M Performance:
+4.44%
6M Performance:
-23.66%
1Y Performance:
+34.24%
1-Day Range:
$68.10
$70.92
1-Week Range:
$67.02
$71.49
52-Week Range:
$40.00
$99.50
Disc Medicine Inc Stock (IRON) Company Profile
Name
Disc Medicine Inc
Sector
Industry
Phone
(617) 674-9274
Address
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
69.83 | 2.68B | 0 | -241.60M | -201.34M | -6.6167 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Resumed | Stifel | Buy |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-11-25 | Resumed | Raymond James | Strong Buy |
| Feb-27-25 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-04-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-23-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-01-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-09-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-07-23 | Initiated | H.C. Wainwright | Buy |
| May-17-23 | Initiated | Raymond James | Outperform |
| Apr-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-21-23 | Initiated | Stifel | Buy |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Mar-23-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Disc Medicine Inc Stock (IRON) Latest News
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), ... - Caledonian Record
Disc Medicine Investor News: If You Have Suffered Losses in - GlobeNewswire
Disc Medicine (IRON) Study update Summary - Quartr
Disc Medicine, Inc. (IRON) Discusses Clinical Updates on Bitopertin, Selcodebart, and DISC-3405 and Strategic OutlookSlideshow (NASDAQ:IRON) 2026-06-15 - Seeking Alpha
IRON: Bitopertin and selcodebart show strong efficacy in EPP and MF anemia, with pivotal data due Q4 2026 - TradingView
IRON: Durable anemia responses and improved outcomes seen in Phase 2 trials for DISC-0974 and bitopertin - TradingView
Disc Medicine, Inc. $IRON Shares Sold by First Turn Management LLC - MarketBeat
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - The Berkshire Eagle
NEXTBio Capital Management LP Takes $3.40 Million Position in Disc Medicine, Inc. $IRON - MarketBeat
Nicholas Investment Partners LP Sells 39,921 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine, Inc. $IRON Stock Position Lowered by Frazier Life Sciences Management L.P. - MarketBeat
Disc Medicine, Inc. $IRON Shares Sold by Atlas Venture Life Science Advisors LLC - MarketBeat
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Disc Medicine reports positive data for hematology pipeline at EHA 2026 - grafa.com
Disc Medicine presents trial data for blood disorder treatments - Investing.com
Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting - The Manila Times
Disc Medicine Announces Promising RALLY-MF and HELIOS Trial Data at EHA Annual Meeting - Quiver Quantitative
Anemia and light-tolerance gains seen in Disc Medicine studies - Stock Titan
Disc Medicine (IRON) Is Down 8.6% After Mixed Trial Success And FDA Setback What's Changed - Sahm
IRON Reiterated by Wedbush -- Price Target Maintained at $88.00 - GuruFocus
Wedbush Reiterates Outperform Rating for Disc Medicine (NASDAQ:IRON) - MarketBeat
Wedbush Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $88 - Moomoo
IRON Investor News: If You Have Suffered Losses in Disc - GlobeNewswire
LifeSci Capital Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Disc Medicine aligns with FDA on path for bitopertin approval By Investing.com - Investing.com Australia
Disc Medicine, FDA agree on approval path for rare disease drug - Seeking Alpha
Disc Medicine aligns with FDA on path for bitopertin approval - Investing.com
Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria - The Manila Times
Bitopertin EPP trial measures pain-free time in sunlight - Stock Titan
BNP Paribas Financial Markets Has $9.70 Million Stock Position in Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine Stock Slumps After FDA Declines Approval For Inherited Disorder Drug Over Efficacy Concerns - Stocktwits
Assessing Disc Medicine (IRON) Valuation After New Trial Data And Expanded Access Program News - Sahm
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - ACCESS Newswire
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are ... - Caledonian Record
Liquidity Mapping Around (IRON) Price Events - Stock Traders Daily
Diamond Blackfan Anemia Market Unlocking New Revenue - openPR.com
Medpace Deadline: MEDP Investors with Losses in Excess of $100K Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit - PR Newswire
BRTX: Advancing late-stage cell therapies for spine, metabolic, and aesthetic markets with strong IP - TradingView
IRON: Bitopertin advances toward pivotal data and regulatory milestones, targeting broad anemia indications - TradingView
Program provides early access to experimental EPP treatment - Porphyria News
Truist Financial Maintains Disc Medicine(IRON.US) With Buy Rating - Moomoo
A Quick Look at Today's Ratings for Disc Medicine(IRON.US), With a Forecast Between $100 to $118 - Moomoo
Stifel reiterates Disc Medicine stock rating on anemia trial data By Investing.com - Investing.com South Africa
Stifel reiterates Disc Medicine stock rating on anemia trial data - Investing.com
Disc Medicine (IRON) Reports Promising Results from RALLY-MF Pha - GuruFocus
Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
Experimental anemia drug cuts transfusions in myelofibrosis trial - Stock Titan
How Investors May Respond To Disc Medicine (IRON) Expanding Pre-Approval Access To Bitopertin For Porphyria Patients - Yahoo Finance
Disc Medicine Launches Expanded Access Program for Bitopertin for Epp Patients - marketscreener.com
Disc Medicine launches expanded access program for bitopertin By Investing.com - Investing.com South Africa
Disc Medicine launches expanded access program for bitopertin - Investing.com
Disc Medicine Inc Stock (IRON) Financials Data
Revenue
Net Income
Cash Flow
EPS
Disc Medicine Inc Stock (IRON) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Franchi Jean M. | Chief Financial Officer |
Apr 14 '26 |
Sale |
69.24 |
6,257 |
433,234 |
64,333 |
| Franchi Jean M. | Chief Financial Officer |
Apr 13 '26 |
Sale |
69.00 |
400 |
27,600 |
70,590 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):